alexa Alan T Remaley | National Institutes of Health
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Alan T Remaley

Alan T Remaley Alan T Remaley
Lipoprotein Metabolism Section
National Institutes of Health
Tel: +1-301-402-9796
Fax: +1-301-402-1885

Alan T. Remaley, M.D., Ph.D is a medical officer in the Public Health Service at the National Institutes of Health. Dr. Remaley received his B.S. in Biochemistry and Chemistry from the University of Pittsburgh in 1981. He received in 1987 a M.D. and Ph.D. (Biochemistry) degree from the University of Pittsburgh. He completed in 1990 a residency in Clinical Pathology at the University of Pennsylvania and became board certified in Clinical Pathology in 1992. He joined the National Institutes of Health in 1990, as a medical staff fellow, and did a postdoctoral fellowship on lipoprotein metabolism at the Molecular Disease Branch of the National Heart, Lung, and Blood Institute. He became in 1995 a senior staff member of the Department of Laboratory Medicine at the National Institutes of Health, where he directs the Immunoassay and HPLC/Mass Spectrometry laboratories. As of 2005, he became the section chief of the Lipoprotein Metabolism Laboratory at NHLBI. His current research is focused on the mechanism of action of the ABCA1 transporter and its role in HDL metabolism. In addition, he is involved in developing new diagnostic immunoassays and lipoprotein assays. He is the author of over 150 publications, mostly in the fields of lipoprotein metabolism and clinical pathology, and has four patents. He is a member of the editorial board for Clinical Chemistry, Open Atherosclerosis, and Journal of Pediatric Clinical Biochemistry. He is a current member of the FDA Advisory Board for Clinical Chemistry/Clinical Toxicology Devices and a member of the CAP Proficiency Test Committee for Special Chemistry. He is a past chair of the Capital Section of the American Association of Clinical Chemistry and the Lipoprotein and Vascular Disease Division of the American Association of Clinical Chemistry.

Research Interest

Mechanism of action of the ABCA1 transporter and its role in HDL metabolism


Global Speakers in the subject

Global Experts in the subject


Anti-inflammatory and Atheroprotective Properties of Omega-3 Polyunsaturated Fatty Acids
Alexander V Sorokin*, Zhi-Hong Yang and Alan T Remaley
Short Communication: J Clin Exp Cardiolog 2016, 7: 478
DOI: 10.4172/2155-9880.1000478
Exploring Genetically Modified Animals for Development of New Atherosclerosis Treatments in NHLBI
Boris L Vaisman, Lita Freeman and Alan T Remaley
Short Communication: J Mol Genet Med 2014, 8:109
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version